BICYCLE THERAPEUTICS PLC business relationships
Companies named in BICYCLE THERAPEUTICS PLC’s 10-K filed 2026-03-17, and public companies whose annual reports name BICYCLE THERAPEUTICS PLC. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 5.4 / 10
- AI naming
- 67 / 100 Top 1% in its category
- Agent readiness
- 5 / 100
- AI adoption
- 0 / 100
Layers: Peptides
Named in BICYCLE THERAPEUTICS PLC’s annual report 10
“Royalties will be payable under the Bayer Collaboration Agreement on a product-by-product and country-by-country basis, commencing on the first commercial sale of each product, until the latest of (a) the expiration of the last valid claim of certain patents licensed by the Company to Bayer, (b) a s...” SEC filing
“On a target-by-target basis, if Novartis elected to progress development candidates directed to such target into further development, Novartis would have been responsible for all future development, manufacturing and commercialization activities and be required to use commercially reasonable efforts...” SEC filing
“On May 4, 2023, we entered into a collaboration and license agreement with Bayer Consumer Care AG, or Bayer, pursuant to which we and Bayer will perform research and discovery activities under a mutually agreed upon research plan during a research term up to a specified number of years per target pr...” SEC filing
“On March 27, 2023, the Company and Novartis entered into a collaboration and license agreement (the "Novartis Collaboration Agreement"), pursuant to which the parties agreed to perform research and discovery activities during a research term of up to a specified number of years per target program to...” SEC filing
“...rs ended December 31, 2025, 2024, and 2023, the Company's revenue has been generated from collaboration agreements with Bayer Consumer Care AG ("Bayer"), Novartis Pharma AG ("Novartis"), Ionis Pharmaceuticals, Inc. ("Ionis"), Genentech, Inc. ("Genentech") and AstraZeneca AB ("AstraZeneca") (Note 9).” SEC filing
“In addition, if Bayer successfully commercializes products arising from the collaboration, Bayer will be required to pay to the Company, on a product-by-product basis, tiered royalties on net sales of products by Bayer, its affiliates or sublicensees at percentages ranging from the mid-single digits...” SEC filing
“..., compared to the year ended December 31, 2024, primarily due to increases of $38.8 million from our collaboration with Novartis primarily due to the recognition of all remaining revenue upon a notice of termination from Novartis in November 2025, effective in February 2026, as well as $5.5 million...” SEC filing
“Our revenue to date has been primarily generated from our current and former research collaborations with Bayer Consumer Care AG, or Bayer, Novartis Pharma AG, or Novartis, Ionis Pharmaceuticals, Inc., or Ionis, and Genentech Inc., or Genentech.” SEC filing
“The Company concluded that the exercise of each Expansion Option, including the option to a specified Targeting Arm for Genentech Collaboration Program #3, is accounted for as a continuation of the existing contract as the customer decided to purchase additional goods and services contemplated in th...” SEC filing
“Genentech collaboration deferred revenue” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.